384 related articles for article (PubMed ID: 36769582)
1. Improving Management of Portal Hypertension: The Potential Benefit of Non-Etiological Therapies in Cirrhosis.
Bitto N; Ghigliazza G; Lavorato S; Caputo C; La Mura V
J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769582
[TBL] [Abstract][Full Text] [Related]
2. Pathophysiology and a Rational Basis of Therapy.
Gracia-Sancho J; Maeso-Díaz R; Bosch J
Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
[TBL] [Abstract][Full Text] [Related]
3. Future Pharmacological Therapies of Portal Hypertension.
Ortiz GA; Garcia-Tsao G
Curr Hepatol Rep; 2019 Mar; 18(1):36-48. PubMed ID: 35722634
[TBL] [Abstract][Full Text] [Related]
4. [Baveno VII - Renewing consensus in portal hypertension: personalized care for portal hypertension].
Li XM; Luo BH; Wang ZY; Yuan J; Han GH
Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):21-29. PubMed ID: 35152666
[TBL] [Abstract][Full Text] [Related]
5. New cellular and molecular targets for the treatment of portal hypertension.
Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
Fortea JI; Zipprich A; Fernandez-Mena C; Puerto M; Bosoi CR; Almagro J; Hollenbach M; Bañares J; Rodríguez-Sánchez B; Cercenado E; Clément MA; Rose CF; Bañares R; Vaquero J; Ripoll C
Liver Int; 2018 Jan; 38(1):102-112. PubMed ID: 28665498
[TBL] [Abstract][Full Text] [Related]
7. Infection as a Trigger for Portal Hypertension.
Steib CJ; Schewe J; Gerbes AL
Dig Dis; 2015; 33(4):570-6. PubMed ID: 26159275
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies for portal hypertension in cirrhosis.
Nair H; Berzigotti A; Bosch J
Expert Opin Emerg Drugs; 2016 Jun; 21(2):167-81. PubMed ID: 27148904
[TBL] [Abstract][Full Text] [Related]
9. Vascular Targets for the Treatment of Portal Hypertension.
Brusilovskaya K; Königshofer P; Schwabl P; Reiberger T
Semin Liver Dis; 2019 Nov; 39(4):483-501. PubMed ID: 31315135
[TBL] [Abstract][Full Text] [Related]
10. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents.
Zaccherini G; Tufoni M; Bernardi M; Caraceni P
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640608
[TBL] [Abstract][Full Text] [Related]
11. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
[TBL] [Abstract][Full Text] [Related]
12. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.
Iwakiri Y; Trebicka J
JHEP Rep; 2021 Aug; 3(4):100316. PubMed ID: 34337369
[TBL] [Abstract][Full Text] [Related]
13. [Long-term drug treatments to improve prognosis of patients with liver cirrhosis and to prevent complications due to portal hypertension].
Holstege A
Z Gastroenterol; 2019 Aug; 57(8):983-996. PubMed ID: 31398770
[TBL] [Abstract][Full Text] [Related]
14. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.
Gunarathne LS; Rajapaksha H; Shackel N; Angus PW; Herath CB
World J Gastroenterol; 2020 Oct; 26(40):6111-6140. PubMed ID: 33177789
[TBL] [Abstract][Full Text] [Related]
15. Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats.
Pietrosi G; Fernández-Iglesias A; Pampalone M; Ortega-Ribera M; Lozano JJ; García-Calderó H; Abad-Jordà L; Conaldi PG; Parolini O; Vizzini G; Luca A; Bosch J; Gracia-Sancho J
Liver Int; 2020 Oct; 40(10):2500-2514. PubMed ID: 32996708
[TBL] [Abstract][Full Text] [Related]
16. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pose E; Napoleone L; Amin A; Campion D; Jimenez C; Piano S; Roux O; Uschner FE; de Wit K; Zaccherini G; Alessandria C; Angeli P; Bernardi M; Beuers U; Caraceni P; Durand F; Mookerjee RP; Trebicka J; Vargas V; Andrade RJ; Carol M; Pich J; Ferrero J; Domenech G; Llopis M; Torres F; Kamath PS; Abraldes JG; Solà E; Ginès P
Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):31-41. PubMed ID: 31607677
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic prevention of variceal bleeding and rebleeding.
Baiges A; Hernández-Gea V; Bosch J
Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
[TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension.
Iwakiri Y
Liver Int; 2012 Feb; 32(2):199-213. PubMed ID: 21745318
[TBL] [Abstract][Full Text] [Related]
19. Inflammation and portal hypertension - the undiscovered country.
Mehta G; Gustot T; Mookerjee RP; Garcia-Pagan JC; Fallon MB; Shah VH; Moreau R; Jalan R
J Hepatol; 2014 Jul; 61(1):155-63. PubMed ID: 24657399
[TBL] [Abstract][Full Text] [Related]
20. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
